

REVIEW

Open Access



# The economic impact of endemic respiratory disease in pigs and related interventions - a systematic review

Marloes Boeters<sup>1\*</sup>, Beatriz Garcia-Morante<sup>2,3,4</sup>, Gerdien van Schaik<sup>1,5</sup>, Joaquim Segalés<sup>3,4,6</sup>, Jonathan Rushton<sup>7,8</sup> and Wilma Steeneveld<sup>1</sup>

## Abstract

**Background** Understanding the financial consequences of endemically prevalent pathogens within the porcine respiratory disease complex (PRDC) and the effects of interventions assists decision-making regarding disease prevention and control. The aim of this systematic review was to identify what economic studies have been carried out on infectious endemic respiratory disease in pigs, what methods are being used, and, when feasible, to identify the economic impacts of PRDC pathogens and the costs and benefits of interventions.

**Results** By following the PRISMA method, a total of 58 studies were deemed eligible for the purpose of this systematic review. Twenty-six studies used data derived from European countries, 18 from the US, 6 from Asia, 4 from Oceania, and 4 from other countries, i.e., Canada, Mexico, and Brazil. Main findings from selected publications were: (1) The studies mainly considered endemic scenarios on commercial fattening farms; (2) The porcine reproductive and respiratory syndrome virus was by far the most studied pathogen, followed by *Mycoplasma hyopneumoniae*, but the absence or presence of other endemic respiratory pathogens was often not verified or accounted for; (3) Most studies calculated the economic impact using primary production data, whereas twelve studies modelled the impact using secondary data only; (4) Seven different economic methods were applied across studies; (5) A large variation exists in the cost and revenue components considered in calculations, with feed costs and reduced carcass value included the most often; (6) The reported median economic impact of one or several co-existing respiratory pathogen(s) ranged from €1.70 to €8.90 per nursery pig, €2.30 to €15.35 per fattening pig, and €100 to €323 per sow per year; and (7) Vaccination was the most studied intervention, and the outcomes of all but three intervention-focused studies were neutral or positive.

**Conclusion** The outcomes and discussion from this systematic review provide insight into the studies, their methods, the advantages and limitations of the existing research, and the reported impacts from the endemic respiratory disease complex for pig production systems worldwide. Future research should improve the consistency and comparability of economic assessments by ensuring the inclusion of high impact cost and revenue components and expressing results similarly.

\*Correspondence:  
Marloes Boeters  
l.j.w.boeters@uu.nl

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Keywords** Systematic review, Economic impact, Respiratory Disease, Pigs

## Background

Respiratory disease, referred to as the porcine respiratory disease complex (PRDC) when multiple pathogens and non-infectious factors are involved, is regarded as one of the most serious health problems in contemporary pig production. In Europe, pneumonia and pleuritis are the most frequent lung lesions observed at the slaughterhouse, with prevalence up to 69% and 48%, respectively [1–5]. In the United States, results from the 2012 National Animal Health Monitoring System indicated that respiratory problems were the main cause of deaths in weaned (47.3%) and grower/finisher pigs (75.1%) [6]. Besides increasing mortality, the PRDC is believed to induce production losses through reduced growth rates and a lower feed conversion efficiency [7, 8]. Consequently, respiratory disease remains one of the main reasons for antimicrobial usage in both nursery and growing/finishing pigs [9–11].

The PRDC term was coined to emphasise the complexity of events leading to respiratory disease development, including the involvement of (several) viral and bacterial pathogens as well as environmental, management, and genetic factors [12, 13]. Pathogens involved in the PRDC vary considerably in different countries, regions, and herds over time [14, 15]. The most common primary viral agents include porcine reproductive and respiratory syndrome virus (PRRSV), porcine circovirus 2 (PCV-2), and swine influenza virus (SIV) [12, 13, 16]. Other primary pathogens such as pseudorabies virus and porcine respiratory coronavirus are reported but they have less impact on today's porcine health [17]. The bacterial species involved in this disease complex are traditionally distinguished between primary or initiators, such as *Mycoplasma (M.) hyopneumoniae*, and *Actinobacillus (A.) pleuropneumoniae*, and secondary or follower pathogens (e.g., *Pasteurella multocida*, *Streptococcus suis* and *Bordetella bronchiseptica*) [12, 13, 16]. The presence of various infectious agents in cases of PRDC leads to complex and potentially synergistic interactions that can increase the severity and duration of clinical signs and lesions, as well as the economic consequences [17].

As economic margins on pig farms are generally small [18], it is valuable to understand costs caused by endemically prevalent individual and co-existing pathogens within the PRDC, as there may be opportunities to increase farm profitability by controlling or preventing these infections. Therefore, estimates of costs and benefits of mitigation measures, can support decision-making regarding disease control at farm, integration system, regional and national levels.

Although one would expect the economic impact of respiratory disease to be well studied for the abovementioned reasons, no review or meta-analysis exists that maps the current state of economic research in this field. The economic implications of pathogens involved in the PRDC are likely to be heavily impacted by the variety in production systems and endemically prevalent strains of different pathogens across countries, as well as by the applied economic methods. These methods are defined by both the type of economic analysis (e.g. basic cost computations, partial budget analysis, cost-benefit analysis) and the cost components considered in this analysis (e.g. labour costs, feed costs, veterinary costs). Thus, the aim of this systematic review was to identify what economic studies have been carried out on infectious endemic respiratory disease in pigs, what economic methods are being used, and, when feasible, to identify the economic impacts of specific or co-existing PRDC pathogens and the costs and benefits of interventions.

## Materials and methods

A systematic literature review was conducted to identify relevant economic research on infectious endemic respiratory disease in pigs and related interventions. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines were followed [19], without the use of risk-of-bias analysis (e.g. assessing the selection bias, reporting bias per study).

### Literature search

The search for suitable references was conducted in PubMed<sup>®</sup>, Scopus and CAB Abstracts. We restricted the search to studies published after January 1, 1980, and to peer-reviewed original research in English only. The search strings consisted of three parts (topic, population and focus), which were all required to be present in the title or abstract for a study to be included (for the full search strings, please refer to Supplementary file S1). The terms related to respiratory disease (topic) included terminology for both respiratory disease at syndrome level and for specific respiratory pathogens. The pathogens included were the most common infectious agents within the PRDC that are considered endemic in large parts of the world: the viral agents PRRSV, SIV and PCV-2, and the bacterial agents *M. hyopneumoniae* and *A. pleuropneumoniae*. The systematic search was lastly updated on January 23, 2023.

### Selection of studies

The abstracts obtained from the search were screened by two independent reviewers (co-authors MB and BGM).

Studies were excluded when their main focus was not on respiratory disease in pigs and/or when no mention was made of an impact on either production parameters (e.g. average daily gain, mortality or feed conversion ratio) or on costs or revenues. The two reviewers compared and merged their findings and created a list of studies for the full text review, which was likewise carried out independently by MB and BGM. At this stage, only studies were included when the full text was available, when the report provided a full (e.g., farm budget analysis, cost-benefit analysis) or partial financial evaluation (e.g., cost analysis, basic calculation of medication costs), and when all calculated changes in economic outputs could be attributed to respiratory disease or to the interventions aiming to reduce or control the disease.

In addition, all open-access issues from the Journal of Swine Health and Production (JSHAP) were manually checked, as this journal is not indexed in a number of databases. Studies that met the screening and eligibility criteria were included. Lastly, reference lists and citations of all selected studies were examined for additional studies that met all inclusion criteria (literature snowballing).

#### Data extraction

Data from the eligible studies were manually extracted by MB and BGM (not independently) and an online spreadsheet for data entry was used. These metadata included study characteristics related to publication (authors, year of publication, country and journal), study focus (syndrome or pathogen level, disease or intervention, unit of interest, farm type and animal age-group), study design (observational, experimental or simulation model) and economic methodology (type of economic evaluation, cost/revenue components, reported economic outcomes and currency). Additionally, we registered the origin of the data used in each study (e.g. primary data collected by the authors, expert opinion, data from scientific literature) and whether the paper mentions the testing of or accounting for the presence of other PRDC pathogens. All collected data are summarized in the text and provided in the Supplementary Files. Where we provide economic outcomes from the included studies, we adjusted the reported study outcomes for inflation using an online tool (<https://in2013dollars.com/>) and converted the original currency to euros using a currency converter tool (<https://cuex.com/en/>) (last applied on September 29, 2023). Where applicable, simple calculations were performed to reach a common unit to express the study results, such as the economic impact per fattening pig.

## Results

### Overview of the included studies


The combination of search terms in the selected databases resulted in 1,940 studies (Fig. 1). In total, 651

non-duplicate citations were screened, and those that did not meet our previously defined screening criteria were excluded, leaving a total of 114 studies. After the final selection, 58 studies were deemed eligible for the purpose of this systematic review, including results from snowballing and JSHAP. The full list of references obtained from the systematic search is available in Supplementary file S2.

### Characteristics of included studies

Detailed characteristics of the studies included in this review are presented in Tables 1 and 2. Overall, the studies were classified into those focused on the economic impact of the disease (23/58; Table 1) and those assessing economics of interventions to prevent and/or control disease (33/58; Table 2). Two studies analysed both the impact of disease and of interventions [20, 21]. Most intervention-focused studies investigated the effects of vaccination (24/35). Of these studies, seventeen evaluated the costs and benefits of vaccination for a short time period (i.e. in one cycle or one year), while seven evaluated the impact for a longer period. After vaccination, the most studied interventions related to elimination strategies (8/35; i.e. depopulation and repopulation, test and removal, herd closure), for all of which the impacts were studied for a long time period (>1 year). Other interventions that were studied include animal management-related measures (4/35; no mixing of litters, early weaning, selection of pathogen-free gilts, separate housing), medication (3/35), biosecurity (3/35), alternative diet or feed regimen (2/35), and installation of air filtration systems (1/35). Eight of the intervention-focused studies investigated and compared the effects of several interventions.

The studies were conducted in 23 different countries. Twenty-six studies used data derived from European countries, 18 from the US, 6 from Asia, 4 from Oceania, and 4 from other countries, i.e., Canada, Mexico, and Brazil. Considering the period of 1980 until now, we found that over half of the studies (33/58) were published in the last ten years (2013–2022) and, of those, 61% (20/33) focused on PRRSV. Overall, half of the included studies (29/58) analysed the economic impact of PRRSV associated disease and/or its interventions, followed by *M. hyopneumoniae* (13/58). For the remaining pathogens the number of indexed studies was low: three for PCV-2, two for *A. pleuropneumoniae*, and one for SIV. Only in ten of all studies focusing on one specific pathogen, the absence or presence of other specific endemic respiratory pathogens was verified or accounted for. Then, six studies targeted co-infection scenarios (e.g., PRDC). In three of these studies, the co-infection of *M. hyopneumoniae* and PCV-2 was studied, whereas in the remaining studies different combinations of at least three of the



**Fig. 1** Flow diagram illustrating the systematic search strategy for identifying relevant studies. \*JSHAP = Journal of Swine Health and Production

primary pathogens (i.e. PRRSV, SIV, PCV-2, *M. hyopneumoniae*, *A. pleuropneumoniae*) were investigated. Lastly, four studies did not specify the respiratory pathogens involved, instead, they assessed the economic impact of lung lesions. Since the pathogens included in the present review are predominantly endemic worldwide, the economic analyses were mainly applied for

endemic scenarios, although 24% (14/58) of the studies also included epidemic (i.e., outbreak) episodes in their analyses.

Most of the studies were conducted in commercial herds (54/58), with only two Asian studies of smallholder farms with less than 20 sows or 100 fattening pigs [22, 23] and two studies conducted in research facilities [24, 25]. The number of farms (owned by one or more pig

**Table 1** Characteristics of studies evaluating the economic impact of disease caused by endemic respiratory pathogens in pigs

Study	Country	Infection scenario	Infectious agent(s) <sup>1</sup>	No. of farms supplying primary production data <sup>2</sup>	Stage of production	Unit of analysis	Study design	Data source(s) <sup>3</sup>	Reference
Pointon et al. (1985)	Australia	Endemic/Epidemic	Mhp	1	Growing	Pig	Controlled trial	DA; C	[26]
Miller and Dorn (1990)	US	Endemic	NS	13	Breeding and growing	Pig	Cross-sectional	DA	[65]
Brouwer et al. (1994)	Netherlands	Endemic	PRRSV	91	Breeding	Sow	Historical control study	DA; C	[66]
Christensen (1995)	New Zealand	Endemic	Mhp	1	Growing	Percent-age point of pneumonia Farm	Cross-sectional	DA	[67]
Pejsak and Markowska-Daniel (1997)	Poland	Epidemic	PRRSV	1	Breeding and growing	Farm	Historical control study	DA	[68]
Garner et al. (2001)	Australia	Endemic/Epidemic	PRRSV	NA	Breeding and growing	Country, region, farm, and pig	Stochastic model	LG	[38]
Bennett and Ijpelaar (2005)	UK	Endemic	SIV	NA	NR	Country	Deterministic model	LS; E	[69]
Losinger (2005)	US	Endemic/Epidemic	App	NR	Growing	Country	Cobb-douglas production model	DA; LS; LG	[28]
Neumann et al. (2005)	US	Epidemic	PRRSV	10	Breeding and growing	Country and farm	Case-control	DA; LG	[70]
Nieuwenhuis et al. (2012)*	Netherlands	Epidemic	PRRSV	9	Breeding	Sow	Historical control study	DA	[20]
Alarcon, Rushton and Wieland (2013)	UK	Endemic/Epidemic	PCV-2	147	Growing	Country, farm, and pig	Stochastic model	LS; LG; E	[34]
Holtkamp et al. (2013)	US	Endemic	PRRSV	80 breeding farms and 639 groups of growing pigs (No. farms NR)	Breeding and growing	Country, sow, and pig	Cross-sectional	DA; LG	[55]
Nathues et al. (2017)	Germany	Endemic	PRRSV	NA	Breeding and growing	Farm, sow, and pig	Stochastic model	LS; LG; E; C	[35]
Pham et al. (2017) <sup>4</sup>	Vietnam	Endemic	PRRSV	162	Breeding and growing	Farm	Cross-sectional	DA; E; LS; LG	[22]
Valdes-Donoso et al. (2018)	US	Epidemic	PRRSV	16	Breeding	Farm and sow	Historical control study	DA; LG	[71]
Calderón Díaz, Rodrigues da Costa, et al. (2020)	Ireland	Endemic	NS	56	Growing	Farm, pig, and Kg of meat	Stochastic model	DA; LS	[37]
Calderón Díaz, Fitzgerald, et al. (2020)*	Ireland	Endemic	PRRSV, SIV, Mhp	56	Growing	Farm	Stochastic model	DA	[21]
Ferraz et al. (2020)	Brazil	Endemic	Mhp	1	Growing	Pig	Cross-sectional	DA	[72]

**Table 1** (continued)

Study	Country	Infection scenario	Infectious agent(s) <sup>1</sup>	No. of farms supplying primary production data <sup>2</sup>	Stage of production	Unit of analysis	Study design	Data source(s) <sup>3</sup>	Reference
Trevisan et al. (2020)	US	Endemic	PRRSV	20	Breeding and growing	Pig	Cohort	DA; LG	[73]
Paz-Sánchez et al. (2021)	Spain	Endemic	Co-infection	1	Growing	Pig	Cross-sectional	DA; LG	[5]
Renken et al. (2021)	Germany	Endemic	PRRSV	21	Breeding	Farm and sow	Cross-sectional	DA; LS; LG	[39]
Kim et al. (2022)	Korea	Epidemic	PRRSV	1	Breeding and growing	Sow and pig	Historical control study	DA; LS	[74]
Pfuderer et al. (2022)	UK	Endemic	NS	NA	Growing	Pig	Systems dynamics model	DA; LS; LG; A	[27]
Trevisi et al. (2022)	Italy	Endemic	PRRSV	NR	Growing	Pig flow and kg of meat	Cohort	DA	[75]
Zhang et al. (2022)	China	Epidemic	PRRSV	4	Breeding and growing	Sow and pig	Historical control study	DA; LG	[76]

\* Studies focus on both the economic impact of disease and the effects of interventions to prevent/control disease

<sup>1</sup> PRRSV = porcine reproductive and respiratory syndrome virus; PCV-2 = porcine circovirus 2; SIV = swine influenza virus (SIV); Mhp = *Mycoplasma hyopneumoniae*; App = *Actinobacillus pleuropneumoniae*; NS = not specified

<sup>2</sup> NR = number of farms providing primary data is not reported; NA = no primary data is provided by farms

<sup>3</sup> LS = scientific literature; LG = grey literature (e.g. industry reports, websites, proceedings, newsletters, government documents); E = expert(s) opinion; DA = data from authors; C = personal communication; A = author(s) expertise

<sup>4</sup> Studies consider economic impact in smallholder farm(s) or research facility settings, whereas all other studies consider only commercial farm(s)

producers) from which primary data were collected on production performance or health ranged from 1 to 162, with a single farm being investigated in 16 of the studies. Studies on the growing phase (33/58), including weaners and fatteners, predominated over the breeding phase (11/58), although several studies assessed economics in both production phases (14/58). Regarding the expression of economic outcomes, 17 different units of analysis were identified (e.g. pig, herd, farm, Kg meat). In 66% (38/58) of the studies, a singular unit was used, whereas the remaining 34% (20/58) used several units to express economic results. The growing pig was the most extensively used unit of analysis (28/58).

### Methodology applied in included studies

In most of the disease-focused studies (16/25), an observational study design was used in which data were collected cross-sectionally, longitudinally, or retrospectively, with no intervention except for the collection of the data. Of these observational study designs, the cross-sectional study design (7/16) and the historical control study design (6/16), dominated over cohort (2/16) and case-control (1/16) study designs. Across all disease-focused studies, only one controlled trial was performed [26]. The remaining eight studies calculated economic impacts through modelling (8/25); five models were stochastic, one deterministic, one study described the use of a systems dynamics model [27] and one study applied the Cobb-Douglas production function [28]. In three of the modelling studies, input parameters were based on primary data on production performance or health collected on farms. In the remaining five, only secondary data (from scientific literature, grey literature, expert opinion or personal communication) were used. All modelling studies that used secondary data only, performed sensitivity analysis on uncertain input parameters.

Modelling was part of a large share of intervention-focused research, as 11 studies relied on simulation modelling exclusively. Of these studies, four collected primary production data from farms to be used in their models, whereas seven used secondary data only. As before, the modelling studies that used only secondary data performed sensitivity analysis on uncertain input parameters. Additionally, in three intervention-focused studies, controlled trial [29], cohort [30], or cross-sectional [31] study designs were combined with an economic deterministic model. Furthermore, fourteen studies collected data solely by means of a controlled trial and six by means of observational study designs (five historical control studies and one cohort study). One study, by Dee and Molitor [32], entailed a case report describing the attempt of PRRSV elimination on one farm. For detailed information on the study designs per included study, refer to Tables 1 and 2.

Economic methods that were applied in the eligible studies, ranged from basic cost computations to more comprehensive methods commonly used in animal health economics (Table 3). The most utilised methods were basic cost computations (15/58) and cost analysis (14/58), followed by partial budget analysis (12/58). As expected, methods built for comparing the profitability of on-farm changes, i.e. the partial budget and cost-benefit analysis, were almost exclusively applied in intervention-focused studies. In five modelling studies, multiple economic methods were applied [33–37].

Seven studies provided estimates of the economic burden at a national level, of which only two studies included price effects across the industry or looked at changes in consumer and producer surplus due to decreased pork production [28, 38]. The remaining five studies extrapolated farm-level estimates without accounting for additional macro-economic effects. Thus, most studies investigated the financial losses at the farm-level, rather than economic losses. However, to keep the terminology simple, we will keep referring to the calculated impacts as the economic impact.

To calculate the on-farm economic impact, a wide range of cost components were considered across all papers (for detailed information of the components per study, please refer to Supplementary file S3). Studies using the same economic method or focusing on the same disease, often included different cost and revenue components in their calculations (Fig. 2). Overall, the most frequently used cost components were veterinary costs (49/58 studies), feed costs (39/58), and labour costs (26/58); whereas the most frequently used revenue components were reduced carcass value (24/58), fewer growing pigs sold (19/58) and fewer piglets weaned/sold (19/58). The modelling studies that considered the most cost components [33, 36, 37, 39] all reported that feed costs and the reduced revenue from fewer sold piglets or fattening pigs were the costliest components. Although most studies included these components, 19 out of the 58 studies did not consider feed costs, and 24 did not calculate lost revenues due to fewer piglets weaned or fattening pigs sold.

### Pathogen specific costs

Despite the variety in units of analysis, the economic outcomes per study could be converted to a common unit for 17 out of 25 disease-focused studies (Fig. 3a-c). This figure serves as an illustration for the range in reported economic impacts, but it should be noted that study outcomes cannot be merged directly due to the variety in study characteristics and methods of calculation.

Since most intervention-focused studies analysed the benefits of vaccination, the main economic outcomes for these studies are summarised in Table 4. It is evident from

**Table 2** Characteristics of studies evaluating the economic impact of interventions to prevent/control disease caused by endemic respiratory pathogens in pigs

Study	Country	Infection scenario	Infectious agent(s) <sup>1</sup>	Intervention	No. of farms supplying primary production data <sup>2</sup>	Stage of production	Unit of analysis	Study design	Data sources <sup>3</sup>	Reference
Dee (1994)	US	Endemic	Mhp	Medication and early weaning	2	Growing	Pig	Historical control study	DA	[77]
Dee et al. (1996)	US	Endemic	PRRSV	Nursery depopulation	5	Growing	Farm, sow, and pig	Historical control study	DA	[78]
Dee et al. (1997)	US	Endemic	PRRSV	Nursery depopulation	34	Growing	Sow	Historical control study	DA	[79]
Dee and Molitor (1998)	US	Endemic	PRRSV	Elimination (test and removal)	1	Breeding	Sow	Case report	DA; A	[32]
Maes et al. (1998)	Belgium	Endemic	Mhp	Vaccination	5	Growing	Pig	Controlled trial	DA	[42]
Pallares et al. (2000)	Spain	Endemic	Mhp	Vaccination	8	Growing	Pig	Controlled trial	DA	[43]
Kyriakis et al. (2001)	Greece	Endemic	Mhp	Vaccination	1	Growing	Pig	Controlled trial	DA	[80]
Miller et al. (2001)	US	Endemic	Mhp	Vaccination	NA	Growing	Farm	Deterministic model	LS; A	[81]
Pallares et al. (2001)	Spain	Endemic	Mhp	Vaccination	16	Growing	Kg of carcass and kg gained in fattening	Controlled trial	DA	[82]
Maes et al. (2003)	Belgium	Endemic	Mhp	Vaccination	14	Growing	Pig	Controlled trial	DA	[83]
Stipkovits et al. (2003)	Hungary	Endemic	Mhp	Vaccination and medication	1	Growing	Kg of finishing pig marketed	Controlled trial	DA	[84]
Holyoake and Callinan (2006)	Australia	Endemic	Mhp	Vaccination	3	Growing	Pig	Controlled trial	DA; LS; A	[85]
Schaefer and Morrison (2006)	US	Endemic	PRRSV	Elimination (herd closure)	15	Breeding	Herd (farms combined)	Historical control study	DA; A	[86]
Rapp-Gabrielson et al. (2007)	US	Endemic	Co-infection	Vaccination	1	Growing	Carcass value	Controlled trial	DA; LG	[87]
Young et al. (2011) <sup>4</sup>	Canada	Endemic	PCV-2	Vaccination	1	Growing	Pig	Controlled trial	DA; A	[24]
Nieuwenhuis et al. (2012)*	Netherlands	Epidemic	PRRSV	Monitoring, vaccination, and eradication	9	Breeding	Sow	Historical control study	DA	[20]
Alarcon, Rushton, Nathues, et al. (2013)	UK	Endemic	PCV-2	Vaccination, diets, stocking density, biosecurity, and depopulation-repopulation	50	Growing	Farm	Stochastic model	LS; LG; E	[33]
Alonso et al. (2013)	US	Endemic	PRRSV	Air filtration	21	Breeding	Farm, sow, and pig	Cohort / deterministic model	DA; LS	[30]



**Table 2** (continued)

Study	Country	Infection scenario	Infectious agent(s) <sup>1</sup>	Intervention	No. of farms supplying primary production data <sup>2</sup>	Stage of production	Unit of analysis	Study design	Data sources <sup>3</sup>	Reference
Zhang et al. (2014)	Vietnam	Endemic/Epidemic	PRRSV	Vaccination	NA	Growing	Country	Deterministic model	DA; LS; A; E	[57]
Linhares et al. (2015)	US	Endemic	PRRSV	Vaccination	NA	Breeding	Farm	Deterministic & Stochastic model	DA; LS; A	[44]
Ramirez et al. (2015)	US	Endemic	Co-infection	Medication	4	Growing	Pig and Kg of body weight	Controlled trial	DA	[40]
Stygar et al. (2016)	Finland	Epidemic	App	Cleaning, vaccination, and medication	NA	Growing	Pig space unit	Dynamic programming model	LS; A	[88]
Grenshaw et al. (2016) <sup>4</sup>	Canada	Endemic	PRRSV	Feed regimen	1	Growing	Pig	Controlled trial	DA; A	[25]
Kaalberg et al. (2017)	Netherlands	Endemic	Co-infection	Vaccination	1	Growing	Pig	Controlled trial	DA; LG	[89]
Kim et al. (2017)	Korea	Endemic	PRRSV	Vaccination	3	Breeding and growing	Farm	Historical control study	DA; LG	[41]
Zhang et al. (2017) <sup>4</sup>	Cambodia	Epidemic	PRRSV	Vaccination and biosecurity	NA	Breeding and growing	Farm	Deterministic model	DA; LG; LS	[23]
Duivon et al. (2018)	France	Endemic	Co-infection	Vaccination	1	Growing	Sow and pig	Controlled trial	DA; LG	[90]
Nathues et al. (2018)	Germany	Endemic	PRRSV	Depopulation-repopulation, close and roll-over, vaccination, and biosecurity	NA	Breeding and growing	Farm	Stochastic model	LS; A; E	[36]
Silva et al. (2019)	US	Endemic	Mhp	Elimination	70	Breeding and growing	Farm, sow, and pig	Cross-sectional/deterministic model	DA; LS	[31]
Calderón Díaz, Fitzgerald, et al. (2020)*	Ireland	Endemic	Co-infection	Vaccination	56	Growing	Farm	Stochastic model	DA	[21]
Thomann et al. (2020)	Germany	Endemic	PRRSV	Vaccination	NA	Breeding	Country, farm, and sow	Stochastic model	LS; LG; A	[91]
Abelia et al. (2021)	Spain	Endemic/Epidemic	PRRSV	Animal selection	1	Breeding	Sow	Discrete-based event model	DA; LG	[92]
Quezada-Fraide et al. (2021)	Mexico	Endemic	PRRSV	Vaccination	2	Growing	Pig and day of fattening	Cohort study	DA; A	[93]

**Table 2** (continued)

Study	Country	Infection scenario	Infectious agent(s) <sup>1</sup>	Intervention	No. of farms supplying primary production data <sup>2</sup>	Stage of production	Unit of analysis	Study design	Data sources <sup>3</sup>	Reference
Jerlström et al. (2022)	Sweden	Endemic	NS	No litter mixing after weaning and separate gilt management	1	Growing	Farm	Deterministic & stochastic model	LG; E; C;	[94]
Moura et al. (2022)	US	Endemic	PRRSV	Vaccination	9	Growing	Experimental group	Controlled trial / deterministic model	DA; LG	[29]

\* Studies focus on both the economic impact of disease and the effects of interventions to prevent/control disease

<sup>1</sup> PRRSV = porcine reproductive and respiratory syndrome virus; PCV-2 = porcine circovirus 2; SIV = swine influenza virus (SIV); Mhp = *Mycoplasma hyopneumoniae*; App = *Actinobacillus pleuropneumoniae*; NS = not specified

<sup>2</sup> NR = number of farms providing primary data is not reported; NA = no primary data is provided by farms

<sup>3</sup> LS = scientific literature; LG = grey literature (e.g. industry reports, websites, proceedings, newsletters, government documents); E = expert(s) opinion; DA = data from authors; C = personal communication; A = author(s) expertise

<sup>4</sup> Studies consider economic impact in smallholder farm(s) or research facility settings, whereas all other studies consider only commercial farm(s)

this table that there is no common method for expressing the main economic impact of vaccination. Overall, most of the intervention-focused studies (24/35) reported a positive economic impact due to the implementation of the respective intervention, while three reported a negative impact [21, 32, 40] and four a neutral impact [30, 41–43]. In the remaining four intervention-focused studies, the effects of different interventions were compared with each other rather than with a control group [20, 25, 29, 44]. For all outcomes from both disease-focused and intervention-focused studies in their original currency, please refer to Supplementary file S4.

## Discussion

An economic perspective is key to understand the impacts of disease and the intervention options available, and, therefore, to improve decision-making regarding animal health and welfare. This is especially important when endemic diseases are concerned, since their effects are often not easily quantified [45]. The present systematic review is the first in the field aiming to identify the economic impacts of specific or co-existing pathogens involved in the porcine respiratory disease complex (PRDC), and the costs and benefits of interventions. This work additionally reveals the economic evaluation methods that were applied across included studies, including the cost and revenue components that were considered in their calculations.

In an ideal scenario, an estimated disease impact should be completely attributable to the disease that is being analysed. However, often endemic respiratory diseases are multifactorial, and the impact of the disease can be influenced by multiple non-infectious risk factors. In addition, pig herds are often burdened with more than one endemic respiratory disease at the same time under the umbrella of the PRDC [12, 13]. If the whole complex is not carefully studied, this could result in flawed estimates. Consequently, studying the effects of a specific pathogen where multiple disease-causing factors are involved is rather difficult, if not impossible in many cases. Most studies in the present review focused on one respiratory pathogen, and the presence or absence of other pathogen(s) was often not established. Therefore, the reported economic outcomes may not fully be the result of one specific respiratory pathogen only, but will be the product of a complex interaction between infectious agents, management conditions, environment, and genetics [12, 13].

In total, 58 peer-reviewed studies were included within this systematic review. Most of these studies analysed the effects of an intervention, of which nearly half focused on vaccination. With fairly low numbers of studies on PCV-2, *A. pleuropneumoniae* and SIV, the PRRSV was by far the most studied pathogen, followed by *M.*

**Table 3** Economic evaluation methods used in the eligible studies

Method	Description	Number of studies (D I)*
Basic computation	Basic calculation of a cost (e.g., total vaccination purchase costs) or of a reduction in revenues (e.g., reduction of number of piglets weaned * sale price per piglet); or adjustment of one value in an external tool.	5   10
Cost analysis	Calculation or estimation of several or total variable costs (including estimation of reduced revenues).	9   5
Margin over specific variable costs	Revenue minus feed and/or veterinary (medication/vaccination) costs.	0   5
Gross margin	Enterprise outputs minus all variable costs <sup>1</sup> .	5   4
Farm budget	Calculation of the total net profit on a farm, by deducting fixed costs from the gross margin <sup>1</sup> .	5   2
Partial budget	Determining the change in net profit resulting from a change on a farm. Calculated by identifying revenues foregone, extra costs, additional revenue, and reduced costs <sup>1</sup> .	2   10
Cost-benefit analysis	Determining the profitability of programs over an extended period of time, by enumerating benefits and costs and applying a discount rate to convert future values to present values. Consequently, the Net Present Value and Benefit-Cost Ratio can be calculated <sup>1</sup> .	0   2
Other	Types of economic analysis performed by single studies. 1. Economic welfare analysis 2. Cash flow analysis and decision optimization.	1. Disease-focused. (28) 2. Intervention-focused. (33)

\* D=Disease-focused, I=Intervention-focused


<sup>1</sup> Description derived from Dijkhuizen, Morris and Huirne (95)

*hyopneumoniae*. However, it should be noted that most studies on PRRSV were from the United States, thus outcomes were based on the effects of PRRSV-2 genotypes, which tend to be considered more virulent than PRRSV-1 ones, predominantly present in Europe [46]. However, others could not confirm that PRRSV-2 genotypes are more virulent than PRRSV-1 [47, 48]. Nevertheless, estimates of PRRSV impact might be overestimated due to the overrepresentation of studies based on PRRSV-2. Although the difference in strain virulence of PRRSV-1 and PRRSV-2 genotypes shows perhaps the most clear difference in disease impact due to differentiated virus species, many studies have shown a variety of genotypes for a respiratory pathogen circulating and evolving within

continents, countries, and even within the same swine operation over time [49–52]. The evolution of genotypes may influence not only their virulence, but also their resistance to treatments and vaccine efficacy [53, 54].

An additional factor adding to the variation in economic impact is the variety in production systems and the overall industry structure across countries. Comparing the production losses on a commercial fattening farm in the United States [55] to the losses for a smallholder breeding farm in Vietnam [22] provides an evident example, but even within a continent or country vast differences may exist due to, among others, varying genetics of the pigs (e.g. differing productivity or disease resilience), the internal and external climate, the farm's biosecurity or health status, access to high quality raw materials and veterinary services, differing target weights for selling and the size of the farm. External factors such as the amount of international import and export and governmental subsidies or other incentives can also lead to differences in economic losses suffered by the industry due to endemic respiratory disease. As this review covers research from a period of nearly 40 years, the evolution of pig production systems and industries regarding these aspects should be considered when drawing conclusions. It should be stressed that, although the described variation may complicate comparing or merging of study outcomes by means of a meta-analysis [56], this variation in research is essential to understand the range in economic impact from endemic respiratory disease at a global level.

When translating production impact into financial consequences, various limitations arise regarding the applied economic methodology. We observed over seven different economic evaluation methods with a large variety in cost and revenue components used to calculate economic outcomes. With the exception of one study [57], in which the farmers' willingness to pay for a vaccine was estimated, the studies included in this review did not include non-monetary costs (e.g. environmental, social or welfare effects). The methods applied in the eligible studies varied from basic cost calculations to more comprehensive methods such as a farm budget analysis. Even after grouping eligible studies by their applied economic method, it was rare that the same cost and revenue components were used. Although we assume that for most studies, the authors included the components that were most relevant for the specific farms under study, a highly varying level of detail in calculations impacts the comparability of economic outcomes from each study. For instance, while increased feed costs and reduced revenue from fewer weaned or sold pigs were identified as the most important components [33, 36, 37, 39], over a third of all studies did not include one or both components. Although these studies do not provide a specific reason for not including these components, it is recognised that




**Fig. 2** Cost and revenue components considered in economic analyses of studies on PRRSV. \* Other components include penalties, subsidies/compensation and industry effects

in a number of them calculating the economic impact of a disease or an intervention was not the primary objective. Leaving out these important cost components may, therefore, be suitable for their respective study aims, but referring to the results as true economic impact estimates will lead to biased conclusions and comparisons with other study outcomes, as the total costs are underestimated. Additionally, the amount of feed costs per kg of carcass can differ greatly between countries, especially

between continents [58]. This fact additionally holds for revenues per kg of carcass and the costs of medicines and vaccines [58, 59]. Moreover, the prices of feed and raw materials are volatile and particularly rising in Europe during the last few years [60], which further impacts the comparability of economic outcomes estimated during different time periods.

While keeping the differences in economic evaluation methods, their level of detail and the differences in



**Fig. 3** Economic impact of disease caused by endemic respiratory pathogens. The economic impact is expressed in decreased profit (in euros) per sow-year (a), per nursery pig (b), and/or, per fattening pig (c). Circles indicate a single reported outcome, whereas boxplots represent a range of economic outcomes from one study (e.g. when different scenarios with varying disease severity were considered, or when economic losses were reported for multiple farms separately). Reported outcomes were adjusted for inflation up until the year 2023 and converted to euros as a common currency. Studies that are marked with an \*, did not include feed costs as a component in their economic analysis

**Table 4** Economic impact of vaccination against endemic respiratory diseases in pigs

Study	Economic outcome in euros	Unit	Reference
<b>Co-infections</b>			
Rapp-Gabrielson et al. (2007) <sup>1</sup>	12.91, 7.82, 9.57	Increased value per carcass for three different vaccines (compared to control)	[87]
Kaalberg et al. (2017) <sup>2</sup>	3.67	Benefit per finisher	[89]
Duivon et al. (2018) <sup>2</sup>	2.16	Benefit per finisher	[90]
<b>Porcine reproductive and respiratory syndrome virus</b>			
Zhang et al. (2014)	2.3–4.5	Benefit-cost ratio	[57]
Moura et al. (2022)	1.83	Benefit-cost ratio	[29]
Kim et al. (2017)		Difference in medication costs not significant	[41]
Linhaires et al. (2015)	32,345	Difference in opportunity costs between modified-live virus vaccination and field-virus inoculation for a 1,000 sow breeding herd	[44]
Zhang et al. (2017)	155.20–316.68	Increased net profits per farm (two-sow breeder; five-pig fattener; single-sow, three-pig farrow-to-finish)	[23]
Thomann et al. (2020)	1) 211–422 2) 184–335	Median annual benefits per sow of (1) vaccinating sows and piglets and (2) Vaccinating only sows	[91]
Quezada-Fraide et al. (2021)	2.14	Difference in costs per weaned pig between vaccinating sows and piglets and vaccinating sows only	[93]
<b><i>Mycoplasma hyopneumoniae</i></b>			
Maes et al. (1998)		Difference in curative parental medication costs not significant	[42]
Pallarés et al. (2000)		Difference in medication costs not significant	[43]
Kyriakis et al. (2001)	0.46, 0.36	Reduced medication cost per pig for two different vaccination schemes (compared to control)	[80]
Stipkovits et al. (2003)	1) -0.02, -0.06 2) 0.03, 0.08	Difference in margin over feed and medication costs per kg of finishing pig marketed for vaccinating (1) once or (2) twice (compared to 2 control groups)	[84]
Maes et al. (2003)	1.17	Additional return to labour per pig	[83]
Holyoake and Callinan (2006)	4.91	Increase in profit per pig	[85]
Miller et al. (2001)	1) 4,978 2) 13,056	Increased annual profits for farms (1020 fatteners placed) shipping (1) by target weight or (2) on fixed date	[81]
<b>Porcine circovirus 2</b>			
Young et al. (2011)	7.57	Return on investment from vaccination per pig	[24]
Alarcon, Rushton, Nathues, et al. (2013)	1) 24,853 2) 97,206	Mean expected value of vaccination after 5 years for a (1) moderately affected farm (100 sows), (2) severely affected farm (100 sows)	[33]

Reported outcomes were adjusted for inflation up until the year 2023 and converted to euros as a common currency

<sup>1</sup> Pigs were vaccinated against *Mycoplasma hyopneumoniae*

<sup>2</sup> Pigs were vaccinated against *Mycoplasma hyopneumoniae* and porcine circovirus type 2

prices across countries and time in mind, most outcomes from the disease-focused studies could be converted to an economic impact in euros per pig, which gives a very rough impression of the range in economic impact of the PRDC syndrome. The median economic impact of one or several co-existing respiratory pathogen(s) as extracted from all studies, ranged from €1.70 to €8.90 per nursery pig, €2.30 to €15.35 per fattening pig, and €100 to €323 per sow per year. Excluding the studies in which feed costs were not considered, increases the minimum reported costs to €2.90 per nursery pig, €2.80 per fattening pig, and €195 per sow per year. Due to the low numbers of studies on pathogens other than PRRSV, the ranges mainly reflect the significant worldwide impact of PRRSV. It is, therefore, unfeasible to compare and rank the various pathogens according to their economic importance. Furthermore, converting absolute economic

outcomes to a single currency complicates the interpretability and comparability of the study outcomes, as differences exist in the relative importance of the economic losses suffered by farmers from countries of different income levels. Preferably, outcomes would be reported in a relative manner, such as the percent decrease in profits due to disease. However, most often information on farm profits in a non-diseased scenario is lacking.

Nearly all studies reported neutral or positive impacts of implementing an intervention. This suggests that for a wide range of production systems and disease scenarios, implementing an intervention on a farm with endemic respiratory diseases increases farm profits. There may be an outcome reporting bias, with only the favourable interventions reported that can undermine the validity of systematic reviews [61]. However, we have no evidence that this is the case in our systematic review. Apparently,

most studies looked at the effects of vaccination, with very few studies considering long-term sustainable interventions. Where several countries are making efforts to eliminate endemic respiratory diseases completely [62, 63], economic research on long-term interventions (such as improvement of management practices, housing conditions or biosecurity measures) would provide valuable information for countries starting with or expanding the elimination of endemic respiratory pathogens. Besides the low number of studies on an intervention other than vaccination, comparison and ranking of interventions was also made unfeasible by the variation in the expression of results. Future research should use more standardised approaches for economic analyses of interventions with similar outcome metrics. For instance, in human health economics, comparison of control programs is mainly done by determining the cost-effectiveness (e.g. costs per disability-adjusted life-year) or cost-benefit ratio [59]. In the case of interventions requiring a large initial investment, calculations of the payback period or return on investment might be preferred [59].

Although the benefits from a standardised approach seem clear from discussing the limitations in the existing research, developing such an approach poses a challenge. The choice for a specific economic method is often dependent on the data available for the study, as well as the purpose of the study outcomes and the nature of the decision (whether researchers estimate the economic impact at the micro-scale or macro-scale, and for a short- or long-term, etc.). Consequently, the richness in methods could be an advantage, rather than only a limitation, as it will allow better alignment of the studies to the decision process required. It would therefore be of great interest to investigate why different methods or outcomes were chosen over others. Moreover, the industry-level economic burden of respiratory diseases in pigs is not limited to the direct costs, but also includes indirect costs, such as costs suffered by non-affected farms due to biosecurity investments or fluctuations in availability and prices of inputs and outputs. Most studies included in this systematic review focused on farm-level economic impacts, whereas methods well suited to study industry effects, such as the partial equilibrium analysis and econometric models, have not yet been explored. Likewise, economic analyses of the impact of policies to control PRDC pathogens were not found through the search. Therefore, there is currently no clarity on which indirect cost and revenue components from the PRDC seem to be most impactful at industry level. An approach that enhances the understanding of the economic burden of endemic respiratory disease for the entire industry would ideally include a range of economic methods, that captures both the economic impact on the farm, and on the (national or international) industry. Such an approach

is being taken by the Global Burden of Animal Diseases programme and is being tested in different parts of the world [62, 63].

Lastly, restricting the review to only peer-reviewed English literature ensures a certain quality of the work but can also narrow the scope of the review and the results. Including “grey” literature during the search, such as conference abstracts and industry reports, would mostly provide additional cost estimations by non-academic organisations or companies. This could assist with reducing publication bias, but it is important to ensure that the study is relevant to the research question and that it is of sufficient quality to be included in the review [64]. In this case, several non-peer-reviewed sources were identified, but oftentimes these entailed works in progress, pilot studies, or works that did not contain adequate or complete information (e.g. explicit information on cost or revenue components). This, together with the fact that searching for abstracts is resource-intensive and availability is usually compromised, advocated for the inclusion of peer-reviewed records only.

In conclusion, respiratory diseases represent a significant economic burden in pig production, as highlighted by the range in economic impact provided in this systematic review. Future research should improve the consistency and comparability of economic assessments by ensuring the inclusion of high impact cost and revenue components and expressing results similarly. Regardless, the outcomes from this systematic review provide insight in the variation in studies, their methods, their advantages and limitations, and the reported impacts from the endemic respiratory disease complex for pig production systems worldwide.

#### Abbreviations

A. pleuropneumoniae	Actinobacillus pleuropneumoniae
JSHAP	Journal of Swine Health and Production
M. hyopneumoniae	Mycoplasma hyopneumoniae
PCV-2	Porcine circovirus 2
PRDC	Porcine respiratory disease complex
PRRSV	Porcine reproductive and respiratory syndrome virus
SIV	Swine influenza virus

#### Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40813-023-00342-w>.

**Supplementary file S1.** Terms used to build the full search strings. - File provides a table of the terms that were used in the search for eligible literature

**Supplementary file S2.** List of eligible studies. - File provides the full list of studies included in the systematic review

**Supplementary file S3.** Economic methods and cost components per study. - File provides full details on which economic method was applied and which cost components were considered per study

**Supplementary file S4.** Reported economic outcomes per study. - File provides the economic outcomes in their original valuta as reported in each disease-focused and intervention-focused study. The file additionally

includes information on the evaluation period for intervention-focused studies and on whether the economic analysis accounts for the presence/absence of other PRDC pathogens

### Acknowledgements

Not applicable.

### Authors' contributions

Conceptualization: MB, GvS and WS. Literature review and data extraction: MB and BGM. Writing and preparation of draft manuscript: MB and BGM. GvS, WS, JS and JR were involved in discussing draft versions of the manuscript at multiple stages. All authors read, edited and approved the final manuscript.

### Funding

This work has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 101000494 (DECIDE).

### Data Availability

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. All created tables supporting the conclusions of this article are included within the article and its supplementary files.

### Declarations

#### Ethics approval and consent to participate

Not applicable.

#### Consent for publication

Not applicable.

#### Competing interests

Gerdien van Schaik is partly employed at Royal GD; the other authors declare no conflict of interest.

#### Author details

<sup>1</sup>Department of Population Health Sciences, section Farm Animal Health, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands

<sup>2</sup>IRTA. Programa de Sanitat Animal. Centre de Recerca en Sanitat Animal (CRESA), Universitat Autònoma de Barcelona (UAB), Campus, Bellaterra, Catalonia 08193, Spain

<sup>3</sup>WOAH Collaborating Centre for the Research and Control of Emerging and Re-Emerging Swine Diseases in Europe (IRTA-CRESA), Bellaterra 08193, Spain

<sup>4</sup>Unitat Mixta d'Investigació IRTA-UAB en Sanitat Animal, Centre de Recerca en Sanitat Animal (CRESA), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra 08193, Spain

<sup>5</sup>Royal GD, Deventer, the Netherlands

<sup>6</sup>Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, Universitat Autònoma de Barcelona, Bellaterra 08193, Spain

<sup>7</sup>Institute of Infection, Veterinary and Ecological Sciences, School of Health and Life Sciences, University of Liverpool, Liverpool, UK

<sup>8</sup>Global Burden of Animal Diseases (GBADs) Programme, University of Liverpool, Liverpool, UK

Received: 18 April 2023 / Accepted: 7 October 2023

Published online: 17 October 2023

### References

- Fraille L, Alegre A, López-Jiménez R, Nofrarías M, Segalés J. Risk factors associated with pleuritis and cranio-ventral pulmonary consolidation in slaughter-aged pigs. *Vet J.* 2010;184(3):326–33.
- Meyns T, Van Steelant J, Rolly E, Dewulf J, Haesebrouck F, Maes D. A cross-sectional study of risk factors associated with pulmonary lesions in pigs at slaughter. *Vet J.* 2011;187(3):388–92.
- Fablet C, Marois-Créhan C, Simon G, Grasland B, Jestin A, Kobisch M, et al. Infectious agents associated with Respiratory Diseases in 125 farrow-to-finish pig herds: a cross-sectional study. *Vet Microbiol.* 2012;157(1–2):152–63.
- Merialdi G, Dottori M, Bonilauri P, Luppi A, Gozio S, Pozzi P, et al. Survey of pleuritis and pulmonary lesions in pigs at abattoir with a focus on the extent of the condition and herd risk factors. *Vet J.* 2012;193(1):234–9.
- Paz-Sánchez Y, Herráez P, Quesada-Canales Ó, Poveda CG, Díaz-Delgado J, Quintana-Montesdeoca MP, et al. Assessment of lung Disease in finishing pigs at slaughter: pulmonary lesions and implications on productivity parameters. *Animals.* 2021;11(12):3604.
- USDA. Swine 2012. Part I: Baseline Reference of Swine Health and Management in the United States. 2015.
- Straw BE, Shin SJ, Yeager AE. Effect of Pneumonia on growth rate and feed efficiency of minimal Disease pigs exposed to *Actinobacillus pleuropneumoniae* and *Mycoplasma hyopneumoniae*. *Prev Vet Med.* 1990;9(4):287–94.
- Cohen LM, Grøntvedt CA, Klem TB, Gulliksen SM, Ranheim B, Nielsen JP, et al. A descriptive study of acute outbreaks of Respiratory Disease in Norwegian fattening pig herds. *Acta Vet Scand.* 2020;62(1):1–13.
- Sarrazin S, Joosten P, Van Gompel L, Luiken RE, Mevius DJ, Wagenaar JA, et al. Quantitative and qualitative analysis of antimicrobial usage patterns in 180 selected farrow-to-finish pig farms from nine European countries based on single batch and purchase data. *J Antimicrob Chemother.* 2019;74(3):807–16.
- Lekagul A, Tangcharoensathien V, Yeung S. Patterns of antibiotic use in global pig production: a systematic review. *Veterinary and Animal Science.* 2019;7:100058.
- USDA. Antimicrobial Use and Stewardship on U.S. Swine Operations. 2017. 2019.
- Brockmeier SL, Halbur PG, Thacker EL. Porcine respiratory disease complex. *Polymicrobial diseases.* 2002:231 – 58.
- Opriessnig T, Giménez-Lirola L, Halbur P. Polymicrobial Respiratory Disease in pigs. *Anim Health Res Reviews.* 2011;12(2):133–48.
- Haimi-Hakala M, Hälli O, Laurila T, Raunio-Saarnisto M, Nokireki T, Laine T, et al. Etiology of acute Respiratory Disease in fattening pigs in Finland. *Porcine Health Management.* 2017;3(1):1–12.
- Qin S, Ruan W, Yue H, Tang C, Zhou K, Zhang B. Viral communities associated with porcine Respiratory Disease complex in intensive commercial farms in Sichuan province, China. *Sci Rep.* 2018;8(1):1–9.
- Sarli G, D'Annunzio G, Gobbo F, Benazzi C, Ostanello F. The role of pathology in the diagnosis of swine Respiratory Disease. *Veterinary Sci.* 2021;8(11):256.
- Saade G, Deblanc C, Bougon J, Marois-Créhan C, Fablet C, Auray G, et al. Coinfections and their molecular consequences in the porcine respiratory tract. *Vet Res.* 2020;51(1):1–19.
- den Broeke A, Leen F, Aluwé M, Van Meensel J, Millet S. The effect of sex and slaughter weight on performance, carcass quality and gross margin, assessed on three commercial pig farms. *Animal.* 2020;14(7):1546–54.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021;372:n71.
- Nieuwenhuis N, Duinhof TF, van Nes A. Economic analysis of outbreaks of porcine reproductive and respiratory syndrome virus in nine sow herds. *Vet Rec.* 2012;170(9):225.
- Calderón Díaz JA, Fitzgerald RM, Shalloo L, Rodrigues da Costa M, Niemi J, Leonard FC, et al. Financial Analysis of Herd Status and Vaccination practices for Porcine Reproductive and Respiratory Syndrome Virus, Swine Influenza Virus, and *Mycoplasma hyopneumoniae* in Farrow-to-Finish Pig farms using a Bio-economic Simulation Model. *Front Vet Sci.* 2020;7:556674.
- Pham HTT, Antoine-Moussiaux N, Grosbois V, Moula N, Truong BD, Phan TD, et al. Financial impacts of Priority Swine Diseases to Pig Farmers in Red River and Mekong River Delta, Vietnam. *Transbound Emerg Dis.* 2017;64(4):1168–77.
- Zhang A, Young JR, Suon S, Ashley K, Windsor PA, Bush RD. Investigating the financial impact of porcine reproductive and respiratory syndrome on small-holder pig farmers in Cambodia. *Trop Anim Health Prod.* 2017;49(4):791–806.
- Young MG, Cunningham GL, Sanford SE. Circovirus vaccination in pigs with subclinical porcine circovirus type 2 Infection complicated by ileitis. *J Swine Health Prod.* 2011;19(3):175–80.
- Crenshaw JD, Campbell JM, Polo J, Bussièrès D. Effects of a nursery feed regimen with spray-dried bovine plasma on performance and mortality of weaned pigs positive for porcine reproductive and respiratory syndrome virus. *J Swine Health Prod.* 2016;25(1).
- Pointon AM, Byrt D, Heap P. Effect of enzootic Pneumonia of pigs on growth performance. *Aust Vet J.* 1985;62(1):13–8.



27. Pfuderer S, Bennett RM, Brown A, Collins LM. A flexible tool for the assessment of the economic cost of pig Disease in growers and finishers at farm level. *Prev Vet Med.* 2022;208:105757.
28. Losinger WC. Economic impacts of reduced pork production associated with the diagnosis of *Actinobacillus pleuropneumoniae* on grower/finisher swine operations in the United States. *Prev Vet Med.* 2005;68(2–4):181–93.
29. Moura CAA, Philips R, Silva GS, Holtkamp DJ, Linhares DCL. Comparison of virus detection, productivity, and economic performance between lots of growing pigs vaccinated with two doses or one dose of PRRS MLV vaccine, under field conditions. *Prev Vet Med.* 2022;204:105669.
30. Alonso C, Davies PR, Polson DD, Dee SA, Lazarus WF. Financial implications of installing air filtration systems to prevent PRRSV Infection in large sow herds. *Prev Vet Med.* 2013;111(3–4):268–77.
31. Silva GS, Yeske P, Morrison RB, Linhares DCL. Benefit-cost analysis to estimate the payback time and the economic value of two *Mycoplasma hyopneumoniae* elimination methods in breeding herds. *Prev Vet Med.* 2019;168:95–102.
32. Dee SA, Molitor TW. Elimination of porcine reproductive and respiratory syndrome virus using a test and removal process. *Vet Rec.* 1998;143(17):474–6.
33. Alarcon P, Rushton J, Nathues H, Wieland B. Economic efficiency analysis of different strategies to control post-weaning multi-systemic wasting syndrome and porcine circovirus type 2 subclinical Infection in 3-weekly batch system farms. *Prev Vet Med.* 2013;110(2):103–18.
34. Alarcon P, Rushton J, Wieland B. Cost of post-weaning multi-systemic wasting syndrome and porcine circovirus type-2 subclinical Infection in England - an economic Disease model. *Prev Vet Med.* 2013;110(2):88–102.
35. Nathues H, Alarcon P, Rushton J, Jolie R, Fiebig K, Jimenez M, et al. Cost of porcine reproductive and respiratory syndrome virus at individual farm level - an economic Disease model. *Prev Vet Med.* 2017;142:16–29.
36. Nathues H, Alarcon P, Rushton J, Jolie R, Fiebig K, Jimenez M, et al. Modeling the economic efficiency of using different strategies to control Porcine Reproductive & respiratory syndrome at herd level. *Prev Vet Med.* 2018;152:89–102.
37. Calderón Díaz JA, Rodrigues da Costa M, Shalloo L, Niemi J, Leonard FC, Crespo-Piazuelo D, et al. A bio-economic simulation study on the association between key performance indicators and pluck lesions in Irish farrow-to-finish pig farms. *Porcine Health Management.* 2020;6(1):1–15.
38. Garner MG, Whan IF, Gard GP, Phillips D. The expected economic impact of selected exotic Diseases on the pig industry of Australia. *Rev Sci Tech.* 2001;20(3):671–85.
39. Renken C, Nathues C, Swam H, Fiebig K, Weiss C, Eddicks M, et al. Application of an economic calculator to determine the cost of porcine reproductive and respiratory syndrome at farm-level in 21 pig herds in Germany. *Porcine Health Manag.* 2021;7(1):3.
40. Ramirez CR, Harding AL, Forteguerra EB, Aldridge BM, Lowe JF. Limited efficacy of antimicrobial metaphylaxis in finishing pigs: a randomized clinical trial. *Prev Vet Med.* 2015;121(1–2):176–8.
41. Kim JJ, Lee JA, Choi HY, Han JH, Huh W, Pi JH, et al. In vitro and in vivo studies of deglycosylated chimeric porcine reproductive and respiratory syndrome virus as a vaccine candidate and its realistic revenue impact at commercial pig production level. *Vaccine.* 2017;35(37):4966–73.
42. Maes D, Deluyker H, Verdonck M, Castryck F, Miry C, Lein A, et al. The effect of vaccination against *Mycoplasma hyopneumoniae* in pig herds with a continuous production system. *Zentralbl Veterinarmed B.* 1998;45(8):495–505.
43. Pallares FJ, Gomez S, Ramis G, Seva J, Munoz A. Vaccination against swine enzootic Pneumonia in field conditions: effect on clinical, pathological, zootechnical and economic parameters. *Vet Res.* 2000;31(6):573–82.
44. Linhares DC, Johnson C, Morrison RB. Economic analysis of immunization strategies for PRRS Control [corrected]. *PLoS ONE.* 2015;10(12):e0144265.
45. Van Der Hogeveen H. Assessing the economic impact of an endemic Disease: the case of mastitis. *Revue Scientifique et Technique (International Office of Epizootics).* 2017;36(1):217–26.
46. Martínez-Lobo F, Díez-Fuertes F, Segalés J, García-Artiga C, Simarro I, Castro J, et al. Comparative pathogenicity of type 1 and type 2 isolates of porcine reproductive and respiratory syndrome virus (PRRSV) in a young pig Infection model. *Vet Microbiol.* 2011;154(1–2):58–68.
47. Ogno G, Sautter CA, Canelli E, García-Nicolás O, Stadejek T, Martelli P, et al. In vitro characterization of PRRSV isolates with different in vivo virulence using monocyte-derived macrophages. *Vet Microbiol.* 2019;231:139–46.
48. Martín-Valls GE, Cortey M, Allepuz A, Illas F, Tello M, Mateu E. Introduction of a PRRSV-1 strain of increased virulence in a pig production structure in Spain: virus evolution and impact on production. *Porcine Health Management.* 2023;9(1):1.
49. Dos Santos LF, Sreevatsan S, Torremorell M, Moreira MA, Sibila M, Pieters M. Genotype distribution of *Mycoplasma hyopneumoniae* in swine herds from different geographical regions. *Vet Microbiol.* 2015;175(2–4):374–81.
50. Pantoja LG, Pettit K, Dos Santos LF, Tubbs R, Pieters M. *Mycoplasma hyopneumoniae* genetic variability within a swine operation. *J Vet Diagn Invest.* 2016;28(2):175–9.
51. Xu Q, Zhang Y, Sun W, Chen H, Zhu D, Lu C, et al. Epidemiology and genetic diversity of PCV2 reveals that PCV2e is an emerging genotype in Southern China: a preliminary study. *Viruses.* 2022;14(4):724.
52. Franzo G, Faustini G, Legnardi M, Cecchinato M, Drigo M, Tucciarone CM. Phylogenetic and phylogeographic reconstruction of porcine reproductive and respiratory syndrome virus (PRRSV) in Europe: patterns and determinants. *Transbound Emerg Dis.* 2022;69(5):e2175–e84.
53. Gutiérrez-Martín CB, Del Blanco NG, Blanco M, Navas J, Rodríguez-Ferri EF. Changes in antimicrobial susceptibility of *Actinobacillus pleuropneumoniae* isolated from pigs in Spain during the last decade. *Vet Microbiol.* 2006;115(1–3):218–22.
54. Meng X. Heterogeneity of porcine reproductive and respiratory syndrome virus: implications for current vaccine efficacy and future vaccine development. *Vet Microbiol.* 2000;74(4):309–29.
55. Holtkamp DJ, Kliebenstein JB, Neumann EJ, Zimmerman JJ, Rottorf HF, Yoder TK, et al. Assessment of the economic impact of porcine reproductive and respiratory syndrome virus on United States pork producers. *J Swine Health Prod.* 2013;21(2):72–84.
56. Lean I, Rabiee A, Duffield TF, Dohoo I. Invited review: use of meta-analysis in animal health and reproduction: methods and applications. *J Dairy Sci.* 2009;92(8):3545–65.
57. Zhang H, Kono H, Kubota S. An Integrated Epidemiological and Economic Analysis of Vaccination against highly pathogenic Porcine Reproductive and Respiratory Syndrome (PRRS) in Thua Thien Hue Province, Vietnam. *Asian-Australas J Anim Sci.* 2014;27(10):1499–512.
58. Holtkamp DJ. Benchmarking the profitability of raising pigs: Country comparisons and factors contributing to their relative advantage or disadvantage in a global market – 2020. *MSD Animal Health;* 2022.
59. Rushton J. The economics of animal health and production. *Cabi;* 2009.
60. IFIP. pig333com [Internet]: IFIP Institut du porc. 2023. Available from: [https://www.pig333.com/articles/ifip-forecasts-for-the-pig-and-feed-markets-in-2023\\_18994/](https://www.pig333.com/articles/ifip-forecasts-for-the-pig-and-feed-markets-in-2023_18994/).
61. Dwan K, Gamble C, Williamson PR, Kirkham JJ, Group RB. Systematic review of the empirical evidence of study publication bias and outcome reporting bias—an updated review. *PLoS ONE.* 2013;8(7):e66844.
62. Rushton J, Huntington B, Gilbert W, Herrero M, Torgerson PR, Shaw A, et al. Roll-out of the Global Burden of Animal Diseases programme. *The Lancet.* 2021;397(10279):1045–6.
63. Huntington B, Bernardo TM, Bondad-Reantaso M, Bruce M, Devleeschauwer B, Gilbert W, et al. Global Burden of Animal Diseases: a novel approach to understanding and managing Disease in livestock and aquaculture. Volume 40. *REVUE SCIENTIFIQUE ET TECHNIQUE-OFFICE INTERNATIONAL DES EPIZOOTIES;* 2021. pp. 567–83. 2.
64. Scherer RW, Saldanha IJ. How should systematic reviewers handle conference abstracts? A view from the trenches. *Syst Reviews.* 2019;8:1–6.
65. Miller GY, Dorn CR. Costs of swine Diseases to producers in Ohio. *Prev Vet Med.* 1990;8(2–3):183–90.
66. Brouwer J, Frankena K, de Jong MF, Voets R, Dijkhuizen A, Verheijden J, et al. PRRS: effect on herd performance after initial Infection and risk analysis. *Vet Q.* 1994;16(2):95–100.
67. Christensen NH. Evaluation of the effects of enzootic Pneumonia in pigs on weight gain and days to slaughter under New Zealand conditions. *N Z Vet J.* 1995;43(4):146–8.
68. Pejsak Z, Markowska-Daniel I. Losses due to porcine reproductive and respiratory syndrome in a large swine farm. *Comp Immunol Microbiol Infect Dis.* 1997;20(4):345–52.
69. Bennett R, Ijpelaar J. Updated estimates of the costs Associated with Thirty Four Endemic Livestock Diseases in Great Britain: a note. *J Agric Econ.* 2005;56(1):135–44.
70. Neumann EJ, Kliebenstein JB, Johnson CD, Mabry JW, Bush EJ, Seitzinger AH, et al. Assessment of the economic impact of porcine reproductive and respiratory syndrome on swine production in the United States. *J Am Vet Med Assoc.* 2005;227(3):385–92.

71. Valdes-Donoso P, Alvarez J, Jarvis LS, Morrison RB, Perez AM. Production losses from an Endemic Animal Disease: Porcine Reproductive and Respiratory Syndrome (PRRS) in Selected Midwest US sow farms. *Front Vet Sci.* 2018;5:102.
72. Ferraz MES, Almeida HMS, Storino GY, Sonalio K, Souza MR, Moura CAA, et al. Lung consolidation caused by *Mycoplasma hyopneumoniae* has a negative effect on productive performance and economic revenue in finishing pigs. *Prev Vet Med.* 2020;182:105091.
73. Trevisan G, Robbins RC, Angulo J, Dufresne L, Lopez WA, Macedo N et al. Relationship between weekly porcine reproductive and respiratory syndrome virus exposure in breeding herds and subsequent viral shedding and mortality in the nursery. *J Swine Health Prod.* 2020;28(5).
74. Kim JH, Kim SC, Kim HJ, Jeong CG, Park GS, Choi JS et al. Insight into the Economic effects of a severe Korean PRRSV1 outbreak in a Farrow-to-nursery farm. *Anim (Basel).* 2022;12(21).
75. Trevisi P, Amatucci L, Ruggeri R, Romanelli C, Sandri G, Luise D, et al. Pattern of antibiotic consumption in two Italian production chains differing by the endemic status for Porcine Reproductive and Respiratory Syndrome. *Front Vet Sci.* 2022;9:840716.
76. Zhang Z, Li Z, Li H, Yang S, Ren F, Bian T, et al. The economic impact of porcine reproductive and respiratory syndrome outbreak in four Chinese farms: based on cost and revenue analysis. *Front Vet Sci.* 2022;9:1024720.
77. Dee SA. Apparent prevention of *Mycoplasma hyopneumoniae* Infection in growing pigs with a low-cost modified medicated-early-weaning program. *J Swine Health Prod.* 1994;2(6).
78. Dee SA, Joo HS, Polson DD. Improved performance of a large pig complex after sequential nursery depopulation. 1996. p. 31–4.
79. Dee SA, Joo HS, Polson DD, Marsh WE. Evaluation of the effects of nursery depopulation of the profitability of 34 pig farms. *Vet Rec.* 1997;140(19):498–500.
80. Kyriakis SC, Alexopoulos C, Vlemmas J, Sarris K, Lekkas S, Koutsoviti-Papadopoulou M, et al. Field study on the efficacy of two different vaccination schedules with HYORESP in a *Mycoplasma hyopneumoniae*-infected commercial pig unit. *J Vet Med B Infect Dis Vet Public Health.* 2001;48(9):675–84.
81. Miller GY, Song Y, Bahnsen PB. An economic model for estimating batch finishing system profitability with an application in estimating the impact of preventive measures for porcine Respiratory Disease complex. *J Swine Health Prod.* 2001;9(4):169–77.
82. Pallares FJ, Gomez S, Munoz A. Evaluation of the zootechnical parameters of vaccinating against swine enzootic Pneumonia under field conditions. *Vet Rec.* 2001;148(4):104–7.
83. Maes D, Verbeke W, Vicca J, Verdonck M, de Kruijff A. Benefit to cost of vaccination against *Mycoplasma hyopneumoniae* in pig herds under Belgian market conditions from 1996 to 2000. *Livest Prod Sci.* 2003;83(1):85–93.
84. Stipkovits L, Laky Z, Abonyi T, Siugzdaite J, Szabo I. Reduction of economic losses caused by mycoplasmal Pneumonia of pigs by vaccination with respiration and by Tiamutin treatment. *Acta Vet Hung.* 2003;51(3):259–71.
85. Holyoake PK, Callinan APL. How effective is *Mycoplasma hyopneumoniae* vaccination in pigs less than three weeks of age? *J Swine Health Prod.* 2006;14(4):189–95.
86. Schaefer N, Morrison R. Effect on total pigs weaned of herd closure for elimination of porcine reproductive and respiratory syndrome virus. *J Swine Health Prod.* 2006;15(3).
87. Rapp-Gabrielson VJ, Hoover T, Sornsen S, Kesl L, Taylor L, Jolie R et al. Effects of *Mycoplasma hyopneumoniae* vaccination in pigs co-infected with *M. hyopneumoniae* and porcine circovirus type 2. *J Swine Health Prod.* 2007;16(1).
88. Stygar AH, Niemi JK, Oliviero C, Laurila T, Heinonen M. Economic value of mitigating *Actinobacillus pleuropneumoniae* Infections in pig fattening herds. *Agric Syst.* 2016;144:113–21.
89. Kaalberg L, Geurts V, Jolie R. A field efficacy and safety trial in the Netherlands in pigs vaccinated at 3 weeks of age with a ready-to-use porcine circovirus type 2 and *Mycoplasma hyopneumoniae* combined vaccine. *Porcine Health Manag.* 2017;3(23):23.
90. Duivon D, Correge I, Hemonic A, Rigaut M, Roudaut D, Jolie R. Field evaluation of piglet vaccination with a *Mycoplasma hyopneumoniae* bacterin as compared to a ready-to-use product including porcine circovirus 2 and *M. hyopneumoniae* in a conventional French farrow-to-finish farm. *Porcine Health Manag.* 2018;4(4):4.
91. Thomann B, Rushton J, Schuepbach-Regula G, Nathues H. Modeling Economic effects of Vaccination against Porcine Reproductive and Respiratory Syndrome: impact of Vaccination Effectiveness, Vaccine Price, and Vaccination Coverage. *Front Vet Sci.* 2020;7:500.
92. Abella G, Pages-Bernaus A, Estany J, Pena RN, Fraile L, Pla-Aragones LM. Using PRRSV-Resilient sows improve performance in endemic infected farms with recurrent outbreaks. *Anim (Basel).* 2021;11(3):1–16.
93. Quezada-Fraide EA, Peñuelas-Rivas CG, Moysén-Albarrán FS, Trujillo-Ortega ME, Martínez-Castañeda FE. Productive performance and costs of swine farms with different PRRS virus vaccination protocols. *Revista Mexicana De Ciencias Pecuarias.* 2021;12(1):205–16.
94. Jerlström J, Huang W, Ehlorsson C-J, Eriksson I, Reneby A, Comin A. Stochastic partial budget analysis of strategies to reduce the prevalence of lung lesions in finishing pigs at slaughter. 2022.
95. Dijkhuizen A, Morris R, Huirne R. Animal health economics: principles and applications. Post Graduate Foundation in Veterinary Science. 1997:25–39.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.